Intestinal Polyps

Intestinal polyps are abnormal growths arising from the mucosal lining of the small intestine, projecting into the lumen. They can be benign or malignant, and are classified histologically as adenomatous, hyperplastic, inflammatory, or hamartomatous. In veterinary medicine, polyps are less common in the small intestine compared to the large intestine, but they can cause significant clinical signs due to obstruction, bleeding, or malignant transformation. They may be solitary or multiple, and can occur in any segment of the small intestine, including the duodenum, jejunum, and ileum. The clinical significance depends on their size, location, and histologic type.

The exact etiology of intestinal polyps in dogs and cats is largely unknown, but several factors are implicated. Chronic inflammation of the intestinal mucosa, such as in inflammatory bowel disease (IBD), may predispose to the development of inflammatory or adenomatous polyps. Genetic mutations, particularly in the adenomatous polyposis coli (APC) gene and K-ras oncogene, are well-documented in human colorectal polyps and are suspected in veterinary cases. Viral etiologies, such as papillomavirus, have been associated with squamous papillomas in the oral cavity and may rarely affect the intestine. Dietary factors, including high-fat, low-fiber diets, and exposure to environmental carcinogens, may contribute. In cats, chronic enteritis and alimentary lymphoma are differentials, but polyps are less common. Breed-specific genetic predispositions are suspected, particularly in certain terrier breeds. Additionally, age-related cellular senescence and impaired DNA repair mechanisms may play a role.

Intestinal polyps are relatively uncommon in dogs and cats compared to gastric or colorectal polyps. They are more frequently diagnosed in middle-aged to older animals, typically over 6 years of age. No strong sex predilection is reported. Certain breeds may be overrepresented, including Boxers, Collies, and German Shepherds, possibly due to a higher incidence of IBD in these breeds. In cats, polyps are rare, but when they occur, they are often associated with chronic enteritis. The exact incidence is unknown, but it is estimated that less than 1% of small intestinal lesions are polyps. Geographic variation is not well-documented, but environmental factors such as diet and toxin exposure may influence prevalence.

The pathophysiology of intestinal polyps involves dysregulation of cell proliferation and apoptosis in the intestinal epithelium. Normally, the mucosal lining undergoes continuous renewal, with a balance between cell division in the crypts and cell death at the villus tips. In polyp formation, this balance is disrupted, leading to focal hyperplasia or neoplasia. Adenomatous polyps arise from dysplastic crypt cells and have malignant potential, progressing through the adenoma-carcinoma sequence. This involves sequential mutations in oncogenes and tumor suppressor genes, such as APC, K-ras, and p53. Inflammatory polyps result from chronic mucosal injury and repair, with infiltration of inflammatory cells and fibrosis. Hamartomatous polyps are developmental malformations with disorganized tissue architecture. As polyps grow, they can cause partial or complete intestinal obstruction, leading to vomiting, diarrhea, and weight loss. Ulceration of the polyp surface can result in chronic blood loss and anemia. Malignant transformation can lead to invasion into the submucosa and metastasis to regional lymph nodes and distant organs.

Predisposing factors for intestinal polyps include chronic inflammatory bowel disease (IBD), which causes persistent mucosal inflammation and increased cell turnover. Genetic predisposition is suspected in certain breeds, such as Boxers and German Shepherds, which have a higher incidence of IBD and possibly polyps. Age is a significant factor, with older animals being more susceptible. Dietary factors, such as low-fiber, high-fat diets, may increase the risk. Exposure to environmental carcinogens, such as tobacco smoke or pesticides, could contribute. Immunosuppression, either due to disease or medication, may impair immune surveillance and allow polyp formation. Concurrent gastrointestinal infections, such as chronic parasitic or bacterial infections, may also predispose.

Clinical signs of intestinal polyps are often nonspecific and may be intermittent. Common signs include chronic vomiting, diarrhea (which may be watery or bloody), weight loss, and decreased appetite. In cases of partial obstruction, signs may include abdominal pain, borborygmus, and postprandial vomiting. Melena or hematochezia may occur if the polyp is ulcerated. In some cases, polyps may be asymptomatic and discovered incidentally during imaging or endoscopy. Physical examination may reveal a palpable abdominal mass if the polyp is large, but this is uncommon. Signs of anemia, such as pale mucous membranes and lethargy, may be present with chronic blood loss. In advanced cases, signs of systemic illness, such as fever and dehydration, may be evident.

Differential diagnoses for intestinal polyps include: 1. **Inflammatory Bowel Disease (IBD)**: Chronic inflammation of the intestinal wall, causing similar clinical signs. Differentiated by histopathology showing lymphocytic-plasmacytic infiltration without polypoid growth. 2. **Intestinal Lymphoma**: Neoplastic proliferation of lymphocytes, often causing diffuse thickening or masses. Differentiated by histopathology and immunophenotyping. 3. **Adenocarcinoma**: Malignant epithelial tumor, often presenting as an annular constricting mass. Differentiated by histopathology showing invasive malignant cells. 4. **Leiomyoma/Leiomyosarcoma**: Smooth muscle tumors, presenting as intramural masses. Differentiated by histopathology and immunohistochemistry. 5. **Intestinal Foreign Body**: Physical obstruction causing acute vomiting and abdominal pain. Differentiated by imaging (radiography, ultrasound) showing a foreign object. 6. **Intussusception**: Telescoping of one intestinal segment into another, causing obstruction. Differentiated by ultrasound showing a target-like lesion. 7. **Granulomatous Enteritis**: Chronic inflammatory condition with granuloma formation, often due to fungal or mycobacterial infection. Differentiated by histopathology and special stains. 8. **Parasitic Infection**: Such as hookworms or roundworms, causing diarrhea and weight loss. Differentiated by fecal examination. 9. **Chronic Intestinal Pseudo-Obstruction**: Motility disorder causing signs of obstruction without a physical mass. Differentiated by imaging and manometry. 10. **Benign Stricture**: Fibrous narrowing due to previous inflammation or surgery. Differentiated by imaging and endoscopy.

The diagnostic algorithm for intestinal polyps begins with a thorough history and physical examination. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, urinalysis, and fecal examination. If anemia or hypoproteinemia is present, further investigation is warranted. Abdominal radiographs may reveal an obstructive pattern or a soft tissue mass, but are often unremarkable. Abdominal ultrasonography is the next step, as it can identify intestinal wall thickening, masses, and lymphadenopathy. If a mass is identified, fine-needle aspiration (FNA) may be performed for cytology, but this is often inconclusive for polyps. Definitive diagnosis requires endoscopic evaluation with biopsy. Upper GI endoscopy allows visualization of the duodenum and proximal jejunum, while ileoscopy can evaluate the ileum. During endoscopy, polyps appear as pedunculated or sessile masses. Biopsy samples should be taken from the polyp and surrounding mucosa. Histopathology is essential to classify the polyp type and assess for malignancy. If endoscopic biopsy is not possible or if the polyp is beyond the reach of the endoscope, surgical exploration and full-thickness biopsy may be necessary. Advanced imaging such as CT or MRI may be used for staging if malignancy is suspected.

Laboratory findings in intestinal polyps are often nonspecific. CBC may show anemia (microcytic, hypochromic if chronic blood loss) or leukocytosis if inflammation is present. Serum biochemistry may reveal hypoproteinemia (hypoalbuminemia) due to protein-losing enteropathy, especially if the polyp is large or multiple. Electrolyte imbalances, such as hypokalemia, may occur with chronic vomiting or diarrhea. Fecal occult blood test may be positive. In cases of inflammation, serum markers such as C-reactive protein (CRP) may be elevated. Specific biomarkers like cobalamin and folate may be abnormal if there is malabsorption. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be checked to rule out pancreatitis. Histopathology of biopsy samples is the gold standard for diagnosis.

Imaging findings for intestinal polyps include: - **Radiography**: Abdominal radiographs may show a soft tissue mass, but are often normal. In cases of obstruction, dilated loops of intestine with gas or fluid may be seen. - **Ultrasonography**: Ultrasound is more sensitive and may reveal a focal intraluminal mass, often with a pedunculated appearance. The mass may be hyperechoic or hypoechoic relative to the surrounding mucosa. Doppler ultrasound can assess vascularity. Thickening of the intestinal wall may be present. - **Computed Tomography (CT)**: CT with contrast can provide detailed images of the intestinal wall and lumen, and is useful for staging if malignancy is suspected. It can detect lymphadenopathy and metastasis. - **Magnetic Resonance Imaging (MRI)**: MRI is less commonly used but can provide excellent soft tissue contrast, useful for evaluating the extent of the lesion. - **Endoscopy**: Endoscopy is the primary imaging modality for direct visualization. Polyps appear as smooth, round, or lobulated masses projecting into the lumen. They may be pedunculated (attached by a stalk) or sessile (flat-based). Biopsy can be taken during endoscopy.

Cytology from FNA of intestinal polyps is often nondiagnostic due to the cohesive nature of epithelial cells. However, it may show clusters of epithelial cells with variable atypia. Histopathology is essential. On biopsy, adenomatous polyps show dysplastic epithelial cells with nuclear hyperchromasia, pseudostratification, and increased mitotic activity. They may be tubular, villous, or tubulovillous. Hyperplastic polyps show elongated crypts with increased cell proliferation but no dysplasia. Inflammatory polyps have a dense infiltrate of inflammatory cells, including lymphocytes, plasma cells, and neutrophils, with fibrosis. Hamartomatous polyps show disorganized tissue elements. Malignant transformation is indicated by invasion of the basement membrane and submucosa. Special stains, such as immunohistochemistry for Ki-67 and p53, may be used to assess proliferative activity and malignant potential.

Treatment of intestinal polyps depends on the type, size, and location, as well as the presence of malignancy. For benign polyps, surgical resection is often curative. Endoscopic polypectomy can be performed if the polyp is accessible, using a snare and electrocautery. For large or multiple polyps, segmental intestinal resection and anastomosis may be necessary. If malignancy is confirmed, surgical resection with wide margins is recommended, and adjuvant chemotherapy may be considered. Supportive care includes fluid therapy for dehydration, antiemetics (e.g., maropitant 1 mg/kg IV/SC q24h) for vomiting, and nutritional support. In cases of inflammatory polyps, treatment of underlying IBD with immunosuppressive drugs (e.g., prednisone 1-2 mg/kg PO q24h, tapering) may be beneficial. Dietary management with a highly digestible, low-residue diet may help reduce clinical signs. Antibiotics (e.g., metronidazole 10-15 mg/kg PO q12h) may be used if bacterial overgrowth is suspected. In all cases, regular monitoring is essential.

The prognosis for intestinal polyps is generally good if they are benign and completely excised. However, adenomatous polyps have malignant potential, and the risk of recurrence or progression to adenocarcinoma is significant. In cases of malignant transformation, the prognosis is guarded, with a median survival time of 6-12 months even with aggressive treatment. Factors that worsen the prognosis include large polyp size (>2 cm), villous histology, high-grade dysplasia, and invasion into the submucosa. Inflammatory polyps associated with IBD may recur if the underlying inflammation is not controlled. Overall, early detection and complete excision offer the best chance for a favorable outcome.

Follow-up for intestinal polyps includes regular re-evaluation every 3-6 months initially, then annually if stable. Serial abdominal ultrasound may be performed to monitor for recurrence. If the polyp was benign and completely excised, no further treatment may be needed, but periodic endoscopy may be recommended for high-risk patients. For malignant polyps, more frequent monitoring with imaging and possibly repeat endoscopy is advised. Blood work, including CBC and biochemistry, should be repeated to monitor for anemia or protein loss. In cases of IBD, ongoing management with immunosuppressive therapy and dietary modification is necessary, with dose adjustments based on clinical response and side effects.

**Pearls**: - Always consider intestinal polyps in middle-aged to older animals with chronic vomiting and diarrhea, especially if there is evidence of blood loss. - Endoscopic biopsy is essential for definitive diagnosis; FNA is often nondiagnostic. - Adenomatous polyps have malignant potential; complete excision is crucial. - In cats, intestinal polyps are rare, but if present, they are often associated with chronic enteritis.

**Pitfalls**: - Do not overlook the possibility of multiple polyps; thorough examination of the entire intestine is necessary. - Avoid assuming that a polyp is benign without histopathology. - Do not delay surgical intervention if there is evidence of obstruction or malignancy. - Be cautious with corticosteroid use in cases of suspected lymphoma, as it may interfere with diagnosis.

Drug protocols for intestinal polyps are primarily supportive and adjunctive. For inflammatory polyps associated with IBD, immunosuppressive therapy is used: - **Prednisone**: 1-2 mg/kg PO q24h, tapering over 4-6 weeks to the lowest effective dose. - **Metronidazole**: 10-15 mg/kg PO q12h, for its immunomodulatory and antibacterial effects. - **Chlorambucil**: 0.1-0.2 mg/kg PO q48h, may be added if response to prednisone is inadequate. - **Cyclosporine**: 5 mg/kg PO q24h, may be used as an alternative. For antiemetic therapy: - **Maropitant**: 1 mg/kg IV/SC q24h, or 2 mg/kg PO q24h. - **Ondansetron**: 0.1-0.2 mg/kg IV q8-12h. For gastrointestinal protectants: - **Omeprazole**: 0.5-1 mg/kg PO q24h. - **Sucralfate**: 0.5-1 g PO q8h. For nutritional support: - **Highly digestible diet**: e.g., Hill's i/d, Royal Canin Gastrointestinal. - **Vitamin B12 (cobalamin)**: 250-500 mcg SC weekly for 4-6 weeks if deficient. For pain management if surgery is performed: - **Buprenorphine**: 0.01-0.02 mg/kg IV/IM q8-12h. - **Meloxicam**: 0.1 mg/kg PO q24h (dogs only, with caution in cats). All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered.

Evidence-based literature on intestinal polyps in dogs and cats is limited. Most information is extrapolated from human medicine and case reports. A study by Willard et al. (2009) reported that adenomatous polyps in the small intestine of dogs are rare but have malignant potential. Another study by Craven et al. (2011) described the endoscopic appearance and treatment of duodenal polyps in dogs, noting that polypectomy is feasible and safe. In cats, a retrospective study by Weiss et al. (2010) found that intestinal polyps are uncommon and often associated with inflammatory bowel disease. Consensus guidelines from ACVIM on chronic enteropathy recommend histopathologic evaluation of intestinal masses to differentiate polyps from neoplasia. There are no large-scale clinical trials on the medical management of polyps, but immunosuppressive therapy is recommended for inflammatory polyps based on anecdotal evidence. Overall, surgical excision remains the standard of care for benign polyps, and chemotherapy is considered for malignant cases, though evidence is sparse.